Evidence map›Paper›PMID 42878689›Full record

ArticleHuman vaccines & immunotherapeutics2026

Safety and immunogenicity of a first-generation modified vaccinia virus Ankara-vectored SARS-CoV-2 vaccine candidate with mRNA-based booster vaccination: A phase 1 trial.

Anahita Fathi, Christine Dahlke, Leonie Mayer, Sibylle C Mellinghoff, Verena Krähling, Sandro Halwe, Helena Müller-Kräuter, Rolf Fendel, Peter Kremsner, Meral Esen and 8 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04569383 (An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04569383 phase1completednot on this map

An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19

TypeinterventionalSponsorUniversitätsklinikum Hamburg-EppendorfRan2020 to 2021Enrolled30ConditionsCovid19ArmsMVA-SARS-2-S vaccinations (days 0 & 28), Comirnaty
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anahita FathiUniversity Medical Centre Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.ORCID 0000-0002-9351-9471
Christine DahlkeUniversity Medical Centre Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.
Leonie MayerUniversity Medical Centre Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.
Sibylle C MellinghoffUniversity Medical Centre Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.
Verena KrählingGerman Center for Infection Research, Partner Site Gießen-Marburg-Langen, Germany.
Sandro HalweGerman Center for Infection Research, Partner Site Gießen-Marburg-Langen, Germany.
Helena Müller-KräuterPhilipps-Universität Marburg, Fachbereich Medizin, Institut für Virologie, Marburg, Germany.
Rolf FendelGerman Center for Infection Research, Partner Site Tübingen, Germany.
Peter KremsnerGerman Center for Infection Research, Partner Site Tübingen, Germany.
Meral EsenGerman Center for Infection Research, Partner Site Tübingen, Germany.
Martha KlugGerman Center for Infection Research, Partner Site Tübingen, Germany.
Marc LütgehetmannGerman Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Germany.
Leonie M WeskammUniversity Medical Centre Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.
MVA-SARS-2-S Study Group
Gerd SutterGerman Center for Infection Research, Partner Site Munich, Germany.
Stephan BeckerGerman Center for Infection Research, Partner Site Gießen-Marburg-Langen, Germany.
Svenja HardtkeUniversity Medical Centre Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.
Marylyn M AddoUniversity Medical Centre Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD), Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid development of effective COVID-19 vaccines was enabled by the parallel assessment of multiple candidates early in the pandemic, including candidates based on the Modified Vaccinia virus Ankara (MVA) vector platform. This Phase 1 trial (NCT04569383) evaluated the MVA-based vaccine candidate MVA-SARS-2-S, expressing the full-length native SARS-CoV-2 spike glycoprotein (Wuhan-HU-1). Between October 2020 and May 2021, 30 healthy, SARS-CoV-2-naive adults received two doses of either 10

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineSARS-CoV-2Vaccinia virusAdultAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineFemaleGenetic VectorsHumansImmunization, SecondaryMaleMiddle AgedSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SyntheticBNT162b2coronavirus vaccinemodified vaccinia virus ankaraMVA-SARS-2-SSARS-CoV-2vector vaccine

Identifiers

PMID42878689
PMCPMC13679322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.